Skip to main content
CJC-1295 Ipamorelin Compound

A research digest of the CJC-1295 + ipamorelin stack: GHRH analogue plus selective GHRP, and what the literature actually measured.

read the full papers here

CJC-1295 Ipamorelin Studies and Source Links

The source list gives each paper’s full name and link. It also shows whether the work used people, animals, cells, or another drug.

Back to the researchRead the effects

Each bracketed number leads to a full source

A strong claim about your sleep or health needs a source. You’ll see a number in brackets beside each CJC-1295 Ipamorelin finding. You can match that number with the full paper in the source list on this page. Some papers tested one small protein. Others tested similar pairs. You can also see when researchers didn’t use the fixed blend. A full paper lets you check more than a short summary can show.

The newest papers still leave the mixed pair untested

We last checked the research from 2025–2026. A 2026 review joined results from tesamorelin trials [7]. Two other reviews looked at broad safety questions. A 2025 paper explained how sports labs find related drugs in urine. That test shows how sports groups can enforce their bans. It tells you nothing about sleep, benefit, or safety. You won’t find a controlled human trial of the fixed pair.

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
  3. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. ↗
  4. Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. ↗
  5. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
  6. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
  7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
  8. Farhy LS, et al. Deterministic construct of amplifying actions of ghrelin on pulsatile growth hormone secretion. Am J Physiol Regul Integr Comp Physiol. 2005;288(6):R1649-63. ↗
  9. Devesa J, et al. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol. 2021;12:636403. ↗
  10. Norman C, et al. Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women. Eur J Endocrinol. 2014;170:121-9. ↗
  11. Fraser GL, et al. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. Eur J Pharmacol. 2009;604:132-7. ↗
  12. Venkova K, et al. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci. 2007;52:2241-8. ↗